Reverse-turn mimetics and method relating thereto
Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
1. A compound having the following formula (VII)
(VI)-R10
wherein (VI) is the formula:
wherein
R a is a bicyclic aryl group having 8 to 11 ring members, which may have 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur;
R b is a monocyclic aryl group having 5 to 7 ring members, which may have 1 to 2 heteroatoms selected from nitrogen, oxygen or sulfur, and aryl ring in the compound may have one or more substituents selected from a group consisting of halogen, hydroxy, cyano, lower alkyl, and lower alkoxy groups;
Rc is a saturated or unsaturated C 1-6 alkyl, C 1-6 alkoxy, perfluoro C 1-6 alkyl group; and
X 1 , X 2 , and X 3 may be the same or different and independently selected from hydrogen, hydroxyl, and halogen; and
Wherein one of R a , R b , R c , X 1 , X 2 , and X 3 is linked to R 10 via Y,
Y is (a) an oxygen, sulfur, or nitrogen atom in R a , R b , and R c , or (b) an oxygen atom in X 1 , X 2 and X 3 when X 1 , X 2 or X 3 is hydroxyl; and
Y—R 10 is hemimalate, dimethylaminoalkylcarbamate, or a salt thereof; or R 10 is hydroxyalkyl, glycosyl, substituted or unsubstituted piperidine oxycarbonyl, or a salt thereof.
2. The compound of claim 1 , wherein the bicyclic aryl group is not substituted.
3. The compound of claim 2 , wherein when not linked to R 10 , the compound is selected from the group consisting of:
4. The compound of claim 1 , when not linked to R 10 , the compound is selected from the group consisting of:
5. The compound of claim 2 , when not linked to R 10 , the compound is
6. The compound of claim 2 , when not linked to R 10 , the compound is selected from the group consisting of:
7. The compound of claim 2 , when not linked to R 10 , the compound is selected from the group consisting of:
8. The compound of claim 1 , wherein the bicyclic aryl group is substituted.
9. The compound of claim 8 , when not linked to R 10 , the compound is
10. The compound of claim 8 , when not linked to R 10 , the compound is selected from the group consisting of:
11. The compound of claim 8 , when not linked to R 10 , the compound is selected from the group consisting of:
12. The compound of claim 8 , when not linked to R 10 , the compound is selected from the group consisting of:
13. A pharmaceutical composition comprising a compound according to claim 1 and pharmaceutically acceptable carrier.
14. The pharmaceutical composition of claim 13 , wherein the bicylcic aryl group is not substituted.
15. The pharmaceutical composition of claim 13 , wherein the bicyclic aryl group is substituted.